Form D · Pharmaceuticals

Bridge Therapeutics, Inc.

Birmingham, AL · CIK 0001724287

Offering snapshot reported Dec 18, 2023 · SEC filing

Reported sold
$321K
Offering amount: $1.5M
Investors reported
22
Form D · investor count
Minimum accepted
$2K
Reported outside-investor minimum
First sale
Oct 27, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 18, 2023Initial$321,000No comparison22SEC filing
Apr 24, 2019Amendment$2,000,000No comparison11SEC filing
Mar 8, 2019AmendmentYet to sellNo comparison0SEC filing
Feb 23, 2018AmendmentYet to sellNo comparison0SEC filing
Feb 22, 2018InitialYet to sellNo comparison0SEC filing

Offering details

Securities
Debt, Other
Exemptions
06c
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-500034
Optional conversion into equity at maturity
N/A, the Company itself is offering the Note

Source: Form D, filed Dec 18, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Kelley S Alton Director, Executive
Jason Bailey Director
David H Bergstrom Director
Diana Harshbarger Director
Elizabeth Kelley Director
Russell Kelley Promoter
Joseph Patrick Mullin Director
Christopher Palutis Director
Tim Peara Executive
Timothy Grant Peara Executive
James Gregory Sullivan Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
217 Country Club Park, Ste Suite 325
Birmingham, AL, 35213